Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 7/20 | 0.44 |
| ▸ | FPR2 | P25090 | 5/20 | 0.44 |
| ▸ | MC4R | P32245 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145666 | 1.00 | FPR1 (0.44) | FPR1FPR2MC4RKCNH2KDM1A | |
| SCHEMBL145665 | 1.00 | FPR1 (0.44) | FPR1FPR2MC4RKCNH2KDM1A | |
| SCHEMBL146482 | 0.91 | KDM1A (0.40) | FPR1FPR2KDM1AEPHX2KDM4D | |
| SCHEMBL146484 | 0.91 | KDM1A (0.40) | FPR1FPR2KDM1AEPHX2KDM4D | |
| SCHEMBL146483 | 0.91 | KDM1A (0.40) | FPR1FPR2KDM1AEPHX2KDM4D | |
| SCHEMBL462835 | 0.89 | FPR1 (0.46) | FPR1FPR2KDM1AEPHX2KDM4D | |
| SCHEMBL462836 | 0.89 | FPR1 (0.46) | FPR1FPR2KDM1AEPHX2KDM4D | |
| SCHEMBL462837 | 0.89 | FPR1 (0.46) | FPR1FPR2KDM1AEPHX2KDM4D | |
| SCHEMBL462830 | 0.87 | KDM1A (0.39) | FPR1FPR2KCNH2KDM1AEPHX2 | |
| SCHEMBL170772 | 0.87 | KDM1A (0.39) | FPR1FPR2KCNH2KDM1AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | FPR1 717/4885FPR2 571/4885MC4R 74/4885 |
| US-20170217936-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | FPR1 1560/4885FPR2 2622/4885MC4R 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.